ENTERO HEALTHCARE SOLU L
ENTERO · General/Diversified · NSE
₹1,260
Current Market Price
Fair Value (DCF)
₹1,449
Margin of Safety
+15.0%
Updated 2d ago
YieldIQ Score
37/100
Piotroski F-Score
5/9
Economic Moat
None
Confidence
28%
ROE
—
Debt/Equity
0.25
WACC
11.1%
Market Cap
₹5,483 Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
9.5%
Return on capital employed
EV / EBITDA
28.6×
Enterprise multiple
Debt / EBITDA
1.9×
Leverage vs earnings
Interest Coverage
4.7×
EBIT covers interest
Current Ratio
2.46×
Short-term liquidity
Asset Turnover
1.87×
Revenue per ₹ of assets
Revenue CAGR (3Y)
26.3%
3-year revenue growth
Revenue CAGR (5Y)
—
5-year revenue growth
DCF Scenario Analysis
vs CMP ₹1,260.2
Bear case
₹328.82
MoS -283.2%
Base case
₹1,449.23
MoS +13.0%
Bull case
₹1,521.69
MoS +17.2%
Ratio Trends
ENTERO · last 4 annual periods
ROE
5.4%
ROCE
9.6%
Operating Margin
—
Debt / Equity
0.22×
PE
—
EV / EBITDA
—
Historical Financials
ENTERO · Annual, last 4 years· amounts in ₹Cr unless noted
| Metric | 2022 | 2023 | 2024 | 2025 | CAGR |
|---|---|---|---|---|---|
| Revenue | ₹2515 Cr | ₹3293 Cr | ₹107 Cr | ₹5065 Cr | +26.3% |
| EBITDA | ₹26.0 Cr | ₹64.9 Cr | ₹121 Cr | ₹207 Cr | +99.6% |
| EBIT | — | — | ₹31.5 Cr | — | +0.0% |
| PAT | ₹-29.9 Cr | ₹-11.6 Cr | ₹37.3 Cr | ₹94.8 Cr | — |
| EPS (diluted) | — | — | ₹10.19 | — | +0.0% |
| CFO | ₹-35.3 Cr | ₹-45.3 Cr | ₹-75.7 Cr | ₹-76.9 Cr | — |
| CapEx | ₹-9.9 Cr | ₹-5.5 Cr | — | ₹-11.3 Cr | — |
| FCF | ₹-45.1 Cr | ₹-50.8 Cr | — | ₹-88.2 Cr | — |
| Total Assets | ₹1126 Cr | ₹1309 Cr | ₹1769 Cr | ₹2703 Cr | +33.9% |
| Total Debt | ₹355 Cr | ₹438 Cr | ₹0.0 Cr | ₹385 Cr | +2.8% |
| Shareholders' Equity | ₹563 Cr | ₹598 Cr | ₹1626 Cr | ₹1770 Cr | +46.5% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
ENTERO vs 5 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
| FDC FDC | — | — | Pending | 11.7% | — |
| NEPHROPLUS NEPHROPLUS | — | — | Pending | 11.5% | — |
| SUVEN SUVEN | — | — | Pending | — | — |
| SUPRIYA SUPRIYA | — | — | Pending | 18.9% | — |
| THYROCARE THYROCARE | — | — | Pending | 16.7% | — |
Click a ticker to view its fair-value analysis.
Dividend History
No dividend events recorded for ENTERO in the last 10 years.
Reverse DCF
Market-implied growth
What FCF growth is priced in →
Risk Analysis
Volatility & drawdown
Risk profile of ENTERO →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for ENTERO →
Compare
Head-to-head with peers
Compare ENTERO side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse ENTERONow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.